Jardiance Cost vs. Alternatives: Comparing SGLT2 Inhibitor Prices and Value

How SGLT2 Inhibitors Work

Sodium-glucose cotransporter 2 inhibitors block glucose reabsorption in the proximal tubule of the kidney, causing roughly 60, 80 grams of glucose to be excreted in urine each day. This mechanism is insulin-independent, which means it works regardless of beta-cell function or insulin resistance severity. The glucosuric effect lowers plasma glucose, but the cardiovascular and renal benefits appear to operate through separate pathways: reduced preload and afterload from mild osmotic diuresis, lower intraglomerular pressure via tubuloglomerular feedback restoration, and shifts in myocardial fuel metabolism toward ketone bodies 1.

Empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin all share this core mechanism. Their selectivity for SGLT2 over SGLT1 differs. Empagliflozin has the highest SGLT2/SGLT1 selectivity ratio (approximately 2,500-fold), while canagliflozin has the lowest among the four (approximately 250-fold), which may explain canagliflozin's slightly greater A1C reduction but also its higher rate of gastrointestinal side effects 2. This pharmacologic distinction matters when interpreting both efficacy and safety, though the clinical significance of selectivity differences remains debated.

Jardiance List Price and Real-World Cost

The wholesale acquisition cost (WAC) for Jardiance sits near $620 per month for both the 10 mg and 25 mg tablets, a pricing structure Boehringer Ingelheim has maintained since 2023 with annual single-digit increases. WAC is not what most patients pay. Net prices after negotiated rebates with pharmacy benefit managers (PBMs) typically run 40 to 60% below list price, placing the true per-member cost for insured patients between $250 and $370 per month 3.

For patients with commercial insurance, the Jardiance Savings Card program can reduce out-of-pocket costs to as low as $10 per month, with a maximum annual benefit that varies by plan year. Patients on Medicare Part D do not qualify for manufacturer copay cards, and their costs depend on formulary tier and coverage phase. Under the Inflation Reduction Act's $2,000 annual out-of-pocket cap (effective January 2025), Medicare beneficiaries using Jardiance see meaningful relief, since the drug's retail price would previously have pushed many into the coverage gap within three to four months.

Uninsured patients face the full WAC. Boehringer Ingelheim offers a patient assistance program (the BI Cares Foundation) for those meeting income eligibility criteria, typically at or below 400% of the federal poverty level 4.

Head-to-Head: Jardiance vs. Farxiga Pricing

Farxiga (dapagliflozin), marketed by AstraZeneca, carries a WAC of approximately $590, $630 per month depending on dose (5 mg or 10 mg). The price difference between Jardiance and Farxiga is functionally negligible at list level. Where patients see separation is formulary positioning.

Most large commercial PBMs (CVS Caremark, Express Scripts, OptumRx) place either Jardiance or Farxiga in a preferred brand tier, but not both. A 2024 analysis of the top 20 commercial formularies found that 11 preferred Farxiga, 7 preferred Jardiance, and 2 listed both at equivalent copay tiers 5. This means a patient's actual cost depends less on the drug's WAC and more on which SGLT2 inhibitor their specific plan has negotiated a better rebate for.

The clinical tradeoff: Jardiance carries the EMPA-REG OUTCOME trial showing a 38% relative risk reduction in cardiovascular death among patients with type 2 diabetes and established cardiovascular disease (hazard ratio 0.62 to 95% CI 0.49, 0.77, P<0.001) 1. Farxiga carries the DAPA-HF trial showing a 26% reduction in the composite of worsening heart failure or cardiovascular death (HR 0.74 to 95% CI 0.65, 0.85, P<0.001), including patients without diabetes 6. Both drugs now hold FDA approval for heart failure across the ejection fraction spectrum. Both drugs also hold CKD indications, with the DAPA-CKD trial (N=4,304) showing a 39% reduction in the renal composite endpoint for dapagliflozin 7 and the EMPA-KIDNEY trial (N=6,609) showing a 28% reduction for empagliflozin 8.

At equivalent net price, a formulary committee's choice often comes down to rebate negotiations rather than clinical differentiation.

Invokana: The Generic Price Disruptor

Canagliflozin (Invokana), the first SGLT2 inhibitor approved by the FDA in 2013, lost patent exclusivity, and generic versions entered the U.S. market in late 2025. Generic canagliflozin is projected to stabilize at $50, $150 per month, representing a 75 to 90% reduction from the brand WAC.

This price point changes the calculus. The CANVAS Program (N=10,142) showed canagliflozin reduced the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 14% (HR 0.86 to 95% CI 0.75, 0.97) 9. The CREDENCE trial (N=4,401) demonstrated a 30% reduction in the renal composite endpoint in patients with diabetic kidney disease 10.

The concern. CANVAS also identified a roughly twofold increase in lower-extremity amputation risk with canagliflozin (6.3 vs. 3.4 per 1,000 patient-years), a signal not confirmed in subsequent large-database studies but one that has not been fully explained 9. The 2020 FDA label revision removed the boxed warning for amputations, but clinical caution persists among prescribers, particularly for patients with peripheral artery disease or prior amputation.

For patients without peripheral vascular disease who need an SGLT2 inhibitor primarily for A1C lowering and cost is a barrier, generic canagliflozin may offer the strongest value proposition. For patients with established heart failure or CKD as the primary indication, the depth of evidence for empagliflozin and dapagliflozin in those specific populations remains stronger.

Steglatro: Lower Price, Weaker Evidence

Ertugliflozin (Steglatro), co-marketed by Merck and Pfizer, carries a WAC around $350, $400 per month. It is the cheapest branded SGLT2 inhibitor. The discount comes with a tradeoff in evidence.

The VERTIS CV trial (N=8,246) tested ertugliflozin in patients with type 2 diabetes and atherosclerotic cardiovascular disease. It met its primary noninferiority endpoint for major adverse cardiovascular events (MACE) but failed to show superiority (HR 0.97 to 95% CI 0.85, 1.11, P=0.67 for superiority) 11. It also failed to reduce the composite of cardiovascular death or heart failure hospitalization as a secondary endpoint, though exploratory analyses showed a reduction in heart failure hospitalization alone.

No dedicated heart failure or CKD outcomes trial exists for ertugliflozin. The ADA Standards of Care and the 2022 AHA/ACC/HFSA heart failure guideline specifically name empagliflozin and dapagliflozin as SGLT2 inhibitors with proven benefit in HFrEF and HFpEF 12. Ertugliflozin is not named. For glucose lowering alone, it is a reasonable and cheaper option. For cardiorenal protection, the evidence gap makes the savings harder to justify.

Cost-Per-Outcome: A Better Metric Than Cost-Per-Pill

A 2021 cost-effectiveness analysis published in Diabetes Care modeled the incremental cost-effectiveness ratio (ICER) of empagliflozin added to standard care versus standard care alone in patients with T2D and established CVD. Over a lifetime horizon, empagliflozin produced an ICER of approximately $42,000 per quality-adjusted life-year (QALY) gained, well below the commonly used $100,000, $150,000/QALY willingness-to-pay threshold 3.

A separate analysis from the same period estimated dapagliflozin's ICER for heart failure (with or without diabetes) at roughly $51,000 per QALY, also cost-effective by conventional standards 13.

These numbers reframe the conversation. A patient paying $300/month net for Jardiance who avoids one heart failure hospitalization (average cost: $15,000, $25,000) has recovered two to seven years of drug cost in a single prevented event. The 2024 ADA Standards of Care explicitly recommend SGLT2 inhibitors with proven cardiovascular benefit (empagliflozin or dapagliflozin) for patients with or at high risk for atherosclerotic CVD, heart failure, or CKD, independent of A1C level and independent of metformin use 14.

Dr. Silvio Inzucchi, who co-chaired the EMPA-REG OUTCOME trial steering committee, stated: "The cardiovascular mortality reduction we observed was unlike anything we had seen with a glucose-lowering agent. This changed how we think about diabetes pharmacotherapy" 1.

Insurance and Formulary Navigation

Navigating SGLT2 inhibitor coverage requires checking three variables: formulary tier, prior authorization requirements, and step therapy mandates.

Formulary tier. Most commercial plans place the preferred SGLT2 inhibitor on tier 2 (preferred brand) with a $30, $75 copay and the nonpreferred option on tier 3 with a $75, $150 copay. Some plans have moved SGLT2 inhibitors to specialty tier following price increases, though this remains uncommon.

Prior authorization. A 2023 survey of 150 U.S. health plans found that 62% required prior authorization for at least one SGLT2 inhibitor, typically requiring documented metformin trial or intolerance, an A1C above a threshold (often 7.0%), and absence of eGFR below the drug's labeled cutoff 5. Plans increasingly waive PA for patients with diagnosed heart failure or CKD, reflecting guideline alignment.

Step therapy. Some plans mandate trial of metformin before approving an SGLT2 inhibitor for diabetes. The 2024 ADA guidelines now recommend SGLT2 inhibitors as first-line therapy alongside metformin, or even as monotherapy, for patients with cardiorenal indications, which gives prescribers use for step therapy overrides.

For patients facing a nonpreferred copay on Jardiance, three options exist: switch to the plan's preferred SGLT2 inhibitor (usually Farxiga), appeal with clinical documentation citing cardiovascular or renal indication, or use the manufacturer copay card to offset the difference.

Medicare Part D Considerations

Medicare beneficiaries represent the largest user group for SGLT2 inhibitors, and their cost structure differs substantially from commercially insured patients. Under the pre-2025 Part D structure, a patient taking Jardiance at $620/month would enter the coverage gap (the "donut hole") within four months, facing 25% coinsurance on the brand price.

The Inflation Reduction Act changed this calculus starting January 2025. The $2,000 annual out-of-pocket maximum means a Medicare patient on Jardiance pays no more than $2,000 total for all Part D drugs in a year, regardless of list price. For patients on Jardiance alone, this effectively caps monthly cost at roughly $167/month ($2,000 ÷ 12), assuming Jardiance is their only or primary Part D expense.

The ADA Consensus Report on managing hyperglycemia in type 2 diabetes notes: "Cost and access remain significant barriers to optimal SGLT2 inhibitor use, particularly among Medicare populations and the uninsured. Clinicians should actively assist patients in identifying coverage pathways" 14.

Generic canagliflozin may further ease this burden for Medicare patients, since generics typically enter Part D formulary preferred tiers with lower cost-sharing.

Combination Products and Hidden Costs

Boehringer Ingelheim markets two combination products containing empagliflozin: Glyxambi (empagliflozin/linagliptin) and Synjardy (empagliflozin/metformin). These carry WACs of $650, $700 per month. Whether they save money depends on whether the patient would otherwise fill two separate prescriptions.

If a patient already takes metformin and their plan places Synjardy on a similar copay tier to Jardiance alone, the combination eliminates one copay and one refill. If Synjardy sits on a higher tier, filling generic metformin ($4, $10/month) plus Jardiance separately is cheaper. Pharmacy benefit structures make this unpredictable without checking the specific plan.

Farxiga has no FDA-approved fixed-dose combination with metformin in the U.S. (Xigduo XR was discontinued). This gives Jardiance a formulary advantage for patients who want a single-pill regimen with metformin.

When Generic Empagliflozin May Arrive

Jardiance's primary U.S. patent expires in 2025, but Boehringer Ingelheim holds additional formulation and method-of-use patents extending potential exclusivity into 2027 to 2028. Several generic manufacturers have filed Abbreviated New Drug Applications (ANDAs) with the FDA. Realistic estimates place generic empagliflozin availability between late 2027 and mid-2028, barring patent litigation settlements that could accelerate or delay entry 4.

When generic empagliflozin arrives, it will likely price in the $30, $100/month range based on typical generic brand erosion curves for high-volume oral medications. Patients whose primary reason for choosing Farxiga or generic canagliflozin is cost should reassess at that point.

Until then, the practical decision tree for most patients remains: check your formulary's preferred SGLT2 inhibitor, apply for manufacturer savings if available, and choose based on your specific cardiorenal risk profile and your physician's clinical judgment.

The lowest copay on a drug with no cardiovascular outcome data (Steglatro) is not the same as the lowest cost of care. For patients with heart failure (EF <40% or preserved), the AHA/ACC/HFSA guidelines assign empagliflozin and dapagliflozin a Class I recommendation (Level of Evidence A), making them standard of care regardless of diabetes status 12.